Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats
- PMID: 15067712
- DOI: 10.1002/jps.20024
Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats
Abstract
This report provides the evidence that pegfilgrastim, which is produced by covalently binding a 20-kDa polyethylene glycol molecule to filgrastim, has decreased renal clearance compared with the native protein, filgrastim. After intravenous administration, the area under the plasma concentration versus time curve values for pegfilgrastim were significantly higher than those for filgrastim, indicating that the clearance was slower for pegfilgrastim. The concentration-time profiles of pegfilgrastim were similar between sham-operated and bilateral nephrectomized rats, suggesting that the kidney had an insignificant role in the elimination of pegfilgrastim. In contrast, bilateral nephrectomy resulted in decreased clearance of filgrastim by 60-75%. These data are consistent with the current knowledge that pegylation of proteins decreases the renal clearance of these conjugated proteins.
Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1367-1373, 2004
Similar articles
-
Pharmacokinetics and pharmacodynamics of pegfilgrastim.Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
-
Pharmacokinetics of pegfilgrastim.Pharmacotherapy. 2003 Aug;23(8 Pt 2):9S-14S. doi: 10.1592/phco.23.9.9s.32888. Pharmacotherapy. 2003. PMID: 12921217 Review.
-
Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model.Pharmacol Res. 2004 Jul;50(1):55-8. doi: 10.1016/j.phrs.2003.12.011. Pharmacol Res. 2004. PMID: 15082029
-
Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.Chemotherapy. 2012;58(5):387-98. doi: 10.1159/000345626. Epub 2012 Dec 28. Chemotherapy. 2012. PMID: 23296266 Review.
-
Novel effects with polyethylene glycol modified pharmaceuticals.Cancer Treat Rev. 2002 Apr;28 Suppl A:3-6. doi: 10.1016/s0305-7372(02)80002-0. Cancer Treat Rev. 2002. PMID: 12173408 Review.
Cited by
-
G-CSF and GM-CSF in Neutropenia.J Immunol. 2015 Aug 15;195(4):1341-9. doi: 10.4049/jimmunol.1500861. J Immunol. 2015. PMID: 26254266 Free PMC article. Review.
-
Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Pharm Res. 2013 Nov;30(11):2795-807. doi: 10.1007/s11095-013-1099-z. Epub 2013 Jun 26. Pharm Res. 2013. PMID: 23801085
-
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.BioDrugs. 2015 Jun;29(3):185-98. doi: 10.1007/s40259-015-0127-4. BioDrugs. 2015. PMID: 25998211 Free PMC article. Review.
-
Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.Cell Prolif. 2009 Dec;42(6):823-37. doi: 10.1111/j.1365-2184.2009.00641.x. Epub 2009 Sep 24. Cell Prolif. 2009. PMID: 19780759 Free PMC article.
-
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.J Clin Oncol. 2010 Mar 10;28(8):1329-36. doi: 10.1200/JCO.2009.24.8872. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142595 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources